Comparisons
Semax vs Adamax: Analogues Compared for Research
By NUPEPS Research TeamNovember 18, 2026

Semax and Adamax share the same seven-residue core, Met-Glu-His-Phe-Pro-Gly-Pro, but they do not share an evidence record. Semax has more than forty years of published laboratory work behind it. Adamax, described by suppliers as an acetylated, adamantane-bearing analogue, has essentially no peer-reviewed primary literature of its own.
That asymmetry is the answer to most comparison questions before any detail begins. A researcher choosing between the two is not choosing between two equally documented compounds with different strengths. The choice is between a characterised parent peptide and a supplier-defined analogue whose structure, behaviour and identity must each be verified analytically, batch by batch.
What Are Semax and Adamax, in One Definition Each?
Semax is a synthetic heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro, abbreviated MEHFPGP. It was developed as a stabilised analogue of the adrenocorticotropic hormone fragment ACTH(4-10), combining the ACTH(4-7) core with a C-terminal Pro-Gly-Pro extension added by design to resist breakdown by several laboratory peptidases.
Adamax is a supplier name, not a literature-defined compound. Suppliers most commonly describe it as an N-acetyl Semax backbone carrying an adamantane-bearing C-terminal group, rendered in shorthand notations such as Ac-MEHFPGP-AG-NH2. No discovery paper, synthesis paper or characterisation paper under that name was identified in the indexed literature for this draft.
Semax vs Adamax at a Glance
| Feature | Semax | Adamax |
|---|---|---|
| Sequence / structure | Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP); ACTH(4-7) core plus Pro-Gly-Pro tail; expected mass about 813.9 Da | Supplier-described N-acetyl Semax backbone plus an adamantane-bearing C-terminal group; descriptions conflict, see the structure section below |
| Origin | Institute of Molecular Genetics, Russian Academy of Sciences; Ashmarin and Myasoedov programme, developed in the 1980s | No named developer, discovery paper or patent identified; circulates through supplier catalogues and secondary summaries only |
| Published record | More than four decades of published work, largely preclinical and largely from one research tradition, including indexed animal pharmacology and gene-expression studies | Essentially none of its own: no discovery, synthesis, characterisation or animal pharmacology dataset under the name Adamax indexed in PubMed |
| Regulatory status | Registered as a medicine in Russia; not approved by the FDA or other Western regulators; supplied elsewhere as research material only | Not registered as a medicine in any jurisdiction identified; not FDA-approved; research chemical only |
| Verification need | Standard batch verification: mass spectrometry identity, chromatographic purity, quantity and sterility for the batch supplied | Deciding verification: mass spectrometry is essential, because supplier descriptions disagree on the expected mass itself, by roughly 48 Da between the two main forms described |
Read as a set, the table shows one documented compound and one inferred compound. Every Semax row can be traced to a journal record, a registry entry or an analytical reference. Every Adamax row traces back to supplier documentation, which is why the verification row carries more weight for Adamax than for its parent.
Where Does Semax Come From?
Semax grew out of mid-twentieth-century work showing that ACTH and its N-terminal fragments influenced learning and behaviour in experimental models independently of hormonal, steroidogenic activity. That behavioural activity was localised to the ACTH(4-10) region, and the Russian programme set out to build a stable analogue retaining it without the hormonal effects.
The programme was based at the Institute of Molecular Genetics of the Russian Academy of Sciences and is associated with Igor Ashmarin and, later, Nikolai Myasoedov. Its design solution kept the ACTH(4-7) sequence and replaced the remaining residues with Pro-Gly-Pro, a proline-rich tail chosen because proline-rich termini resist several peptidases in laboratory systems.
Semax was later registered as a medicine in Russia and studied there for decades, largely in cerebral ischemia models. Most of that literature is preclinical and much appeared in Russian-language journals, so a long record from one tradition is real evidence without being independent international replication. NUPEPS PEPTIDES reviews it in the Semax research guide and lists Semax 10MG for laboratory use.
What Does the Semax Literature Actually Show?
The most frequently cited mechanistic finding concerns brain-derived neurotrophic factor, BDNF, and its receptor TrkB in rat brain. Dolotov and colleagues reported in 2006 that a single application of Semax in rats was followed by measurable changes in hippocampal BDNF protein, TrkB activation and related messenger RNA levels.
The reported values were specific: hippocampal BDNF protein rose about 1.4-fold, TrkB phosphorylation rose about 1.6-fold, BDNF exon III messenger RNA rose about 3-fold, and TrkB messenger RNA rose about 2-fold, alongside changes in conditioned avoidance behaviour in the same animals. Those are rat hippocampus measurements, reported by one research group, in one experimental design.
Citation: Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54-60. PMID: 16996037. DOI: 10.1016/j.brainres.2006.07.108.
Later Semax work widened to gene-expression profiling in ischemia models and to metal coordination chemistry through its histidine residue. Even after four decades, the literature documents downstream effects more firmly than any single molecular target. None of these findings was generated with Adamax, and this comparison transfers no Semax result across to Adamax.
Where Does Adamax Come From?
Adamax has no comparable origin story in the published record. No institute, research programme, named developer, discovery paper or patent for a peptide called Adamax was identified for this draft. The name itself is a portmanteau of adamantyl and Semax, and it circulates through supplier catalogues rather than through journals, registries or conference proceedings.
The absence extends across every category of primary literature. There is no synthesis and characterisation paper establishing its structure, no binding study, no cell study and no animal pharmacology dataset under that name indexed in PubMed. Searches for the name return work on an unrelated machine-learning optimisation algorithm that happens to share the same spelling.
That makes Adamax uncharacterised rather than uninteresting: even a comparative stability experiment against Semax would add genuinely new information, because its published record starts at zero. NUPEPS PEPTIDES sets out the supplier claims and their disagreements in the Adamax research guide and lists Adamax 10MG for laboratory use.
How Is Adamax Described Structurally, and Why Do Descriptions Conflict?
The most common supplier description gives Adamax an N-acetyl cap on the Semax backbone and an adamantane-bearing group at the C-terminus. One widely circulated form is reported at about 1032 Da with the molecular formula C50H69N11O11S. That form includes the adamantane cage, the structural feature that gives the compound its name and its entire design rationale.
Other supplier and laboratory descriptions report a materially different molecule under the same name: a form at about 984 Da, described as an acetylated Semax-based backbone with no adamantane group at all. The difference between the two descriptions is roughly 48 Da, far larger than rounding, salt-form variation or ordinary reporting error between certificates for the same compound.
Two products sold under one name may therefore not be the same molecule. Without a literature reference structure, there is no journal specification against which either description can be judged correct. The only specification available to a researcher is the analytical documentation for the actual batch in hand, checked against the structure the supplier claims for that batch.
This conflict is the practical centre of the comparison. For Semax, a certificate can be checked against a known sequence and a known expected mass. For Adamax, the certificate must first establish which of the conflicting described structures the batch is claimed to be, and only then whether the measured mass matches that claim.
What Is Adamantane, and What Is It Intended to Change?
Adamantane is a rigid, diamond-like cage hydrocarbon with the formula C10H16. It is the smallest cage unit of the diamond lattice, strongly lipophilic and sterically bulky. Medicinal chemists have attached adamantane groups to smaller molecules for decades, and adamantane-bearing structures appear across several established areas of medicinal chemistry and drug design.
The standard review of that chemistry is Wanka, Iqbal and Schreiner, published in Chemical Reviews in 2013. It documents why the cage is used: it raises lipid solubility and membrane partitioning, it can sterically shield nearby bonds, and it changes how a molecule distributes between aqueous and lipid environments in laboratory and medicinal-chemistry systems.
Citation: Wanka L, Iqbal K, Schreiner PR. The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chemical Reviews. 2013;113(5):3516-3604. PMID: 23432396. DOI: 10.1021/cr100264t.
Applied to a Semax backbone, the stated design aims follow directly from that general chemistry. An N-terminal acetyl cap is intended to reduce attack by aminopeptidases, and a lipophilic C-terminal cage is intended to slow breakdown and favour membrane exposure. Both statements describe aims drawn from general adamantane chemistry, not results measured on Adamax itself.
That distinction must stay explicit every time the design is discussed. No published study identified for this draft measured Adamax stability, Adamax lipophilicity, Adamax membrane partitioning or Adamax distribution in any system. Until such measurements exist in the literature, stability and lipophilicity claims for Adamax remain design intentions, however chemically coherent those intentions appear on paper.
Is Adamax Just Stronger Semax?
No published evidence supports that description. Strength comparisons require, at minimum, the same assay run on both compounds under the same conditions, with a defined readout. No such head-to-head dataset for Semax and Adamax was identified in the indexed literature for this draft, in any model, at any point in the record.
Structural analogy cannot substitute for that dataset. A modification intended to slow breakdown could change exposure, distribution, breakdown products or activity in either direction, and Semax fragments have been studied in their own right. Adamax is a Semax-derived design with a plausible rationale and no published pharmacology; any relative potency or duration claim must come from new experiments.
What Can Each Compound Legitimately Be Studied For in the Laboratory?
Semax supports study designs grounded in its own literature: neurotrophin-pathway readouts in neuronal systems, gene-expression responses in ischemia models, and metal coordination chemistry, each framed against published Semax methods and results. A researcher can cite a prior Semax protocol, a prior Semax readout and a prior Semax result when designing and interpreting that laboratory work.
Adamax supports more basic questions: comparative stability time-courses against Semax, measured lipophilicity and membrane partitioning, and physicochemical characterisation would each test a stated design aim directly. Cell-signalling work is best framed as a hypothesis test, with Semax as a comparator arm and the test material analytically confirmed first. Both compounds are supplied by NUPEPS PEPTIDES strictly for laboratory and in vitro research, and this comparison is educational material, not medical advice.
How Do Researchers Verify These Materials Before an Experiment?
Verification starts with identity, and for this pair identity means mass spectrometry. Semax carries an expected mass of about 813.9 Da for its defined sequence. The adamantane-bearing Adamax form described by suppliers carries an expected mass of about 1032 Da, while the conflicting no-adamantane description sits near 984 Da. Those three values are cleanly separable by routine mass spectrometry.
That separation is what makes the measurement decisive here. A batch labelled Adamax that returns a mass near 984 Da does not match the adamantane-bearing structure its name promises, and a batch returning the Semax mass matches neither Adamax description. A certificate reporting a headline purity figure without an observed mass against a stated expected mass leaves the central identity question unanswered.
Purity and quantity are then checked by analytical chromatography, most commonly reversed-phase HPLC, alongside the batch record, and sterility should be reported for the specific batch supplied. NUPEPS PEPTIDES publishes batch Certificates of Analysis at nupeps.com/coas and tests every batch for purity, quantity and sterility, so researchers can complete this check before any experiment begins.
Researchers should inspect the underlying data rather than a summary line alone: the chromatogram, the observed mass against the stated expected mass, and a batch-specific certificate. For Adamax, that inspection substitutes for the literature characterisation this compound does not yet have.
Frequently Asked Questions
Is Adamax just stronger Semax?
No evidence supports that claim. No published head-to-head study comparing Semax and Adamax in the same assay was identified for this draft, and structural analogy does not establish relative strength. Adamax has design aims, drawn from general adamantane chemistry, but no measured potency, duration or activity dataset of its own in the indexed literature.
Does Adamax have any published studies of its own?
Essentially none were identified. No discovery paper, synthesis or characterisation paper, cell study or animal pharmacology dataset under the name Adamax is indexed in PubMed. Searches for the name return an unrelated machine-learning optimisation algorithm. Everything published in this area concerns Semax, adamantane chemistry in general, or other adamantane-bearing compounds, not Adamax itself.
Are Semax study results evidence about Adamax?
No. Semax results, including the Dolotov 2006 BDNF and TrkB findings in rat hippocampus, were generated with Semax and describe Semax. They explain why a modified analogue attracts laboratory interest and they define hypotheses worth testing. They do not measure Adamax, and a terminal modification can change a peptide's behaviour in ways that must be measured rather than assumed.
Why do suppliers describe Adamax with different molecular weights?
Because there is no literature reference structure to settle the description. One widely circulated form is reported near 1032 Da, with formula C50H69N11O11S and an adamantane group included. Another description sits near 984 Da for an acetylated Semax-based backbone with no adamantane group at all. The roughly 48 Da gap means batch mass spectrometry, not the product name, decides identity.
How can a researcher check an Adamax batch before use?
Request the batch-specific Certificate of Analysis and check the observed mass spectrometry mass against the expected mass for the structure the supplier states for that batch, then confirm chromatographic purity and whether quantity and sterility are reported for that batch. NUPEPS PEPTIDES publishes its batch certificates at nupeps.com/coas for exactly this verification step before laboratory work.
Conclusion
Semax and Adamax share a seven-residue core and nothing else of substance. Semax brings a defined sequence, a named research programme, registration in Russia and more than four decades of published laboratory work, including specific, citable measurements. Adamax brings a design rationale, conflicting supplier descriptions and no primary literature of its own.
For laboratory sourcing, the standard follows from that contrast. Semax material is verified against a known expected mass and a published record. Adamax material must first be shown, by batch mass spectrometry, to be the adamantane-bearing structure its name describes. In this comparison, analytical verification is not the final formality; it is the deciding step.
Frequently asked questions
Is Semax vs Adamax: Analogues Compared for Research for human use?
No. All compounds discussed in this guide are strictly for laboratory research use only. Not for human or veterinary use.
Where can I find the Certificate of Analysis?
Certificates of Analysis are available in our COA library. Each batch is third-party tested for purity and identity.
How should research compounds be stored?
Store according to the vial label instructions. Generally, lyophilized compounds should be kept in a cool, dry place away from light. Refer to the specific product documentation for details.
All products are intended strictly for laboratory research and in-vitro use only. Not for human or veterinary consumption, diagnostic, or therapeutic use. Products are not drugs, foods, cosmetics, or dietary supplements and may not be misbranded, misused, or mislabeled.



